170 related articles for article (PubMed ID: 22041173)
1. Design, synthesis, and biological evaluation of a novel series of bisintercalating DNA-binding piperazine-linked bisanthrapyrazole compounds as anticancer agents.
Zhang R; Wu X; Yalowich JC; Hasinoff BB
Bioorg Med Chem; 2011 Dec; 19(23):7023-32. PubMed ID: 22041173
[TBL] [Abstract][Full Text] [Related]
2. The structure-based design, synthesis and biological evaluation of DNA-binding bisintercalating bisanthrapyrazole anticancer compounds.
Hasinoff BB; Liang H; Wu X; Guziec LJ; Guziec FS; Marshall K; Yalowich JC
Bioorg Med Chem; 2008 Apr; 16(7):3959-68. PubMed ID: 18258442
[TBL] [Abstract][Full Text] [Related]
3. The structure-based design, synthesis, and biological evaluation of DNA-binding amide linked bisintercalating bisanthrapyrazole anticancer compounds.
Hasinoff BB; Zhang R; Wu X; Guziec LJ; Guziec FS; Marshall K; Yalowich JC
Bioorg Med Chem; 2009 Jul; 17(13):4575-82. PubMed ID: 19457675
[TBL] [Abstract][Full Text] [Related]
4. Design, synthesis and biological evaluation of a novel series of anthrapyrazoles linked with netropsin-like oligopyrrole carboxamides as anticancer agents.
Zhang R; Wu X; Guziec LJ; Guziec FS; Chee GL; Yalowich JC; Hasinoff BB
Bioorg Med Chem; 2010 Jun; 18(11):3974-84. PubMed ID: 20471276
[TBL] [Abstract][Full Text] [Related]
5. Structure-based design, synthesis and biological testing of piperazine-linked bis-epipodophyllotoxin etoposide analogs.
Yadav AA; Chee GL; Wu X; Patel D; Yalowich JC; Hasinoff BB
Bioorg Med Chem; 2015 Jul; 23(13):3542-51. PubMed ID: 25922181
[TBL] [Abstract][Full Text] [Related]
6. N-fused imidazoles as novel anticancer agents that inhibit catalytic activity of topoisomerase IIα and induce apoptosis in G1/S phase.
Baviskar AT; Madaan C; Preet R; Mohapatra P; Jain V; Agarwal A; Guchhait SK; Kundu CN; Banerjee UC; Bharatam PV
J Med Chem; 2011 Jul; 54(14):5013-30. PubMed ID: 21644529
[TBL] [Abstract][Full Text] [Related]
7. Novel trifluoromethylated 9-amino-3,4-dihydroacridin-1(2H)-ones act as covalent poisons of human topoisomerase IIα.
Infante Lara L; Sledge A; Laradji A; Okoro CO; Osheroff N
Bioorg Med Chem Lett; 2017 Feb; 27(3):586-589. PubMed ID: 27998679
[TBL] [Abstract][Full Text] [Related]
8. A three-dimensional quantitative structure-activity relationship study of the inhibition of the ATPase activity and the strand passing catalytic activity of topoisomerase IIalpha by substituted purine analogs.
Jensen LH; Liang H; Shoemaker R; Grauslund M; Sehested M; Hasinoff BB
Mol Pharmacol; 2006 Nov; 70(5):1503-13. PubMed ID: 16880287
[TBL] [Abstract][Full Text] [Related]
9. Design, synthesis, molecular docking and anti-proliferative evaluations of [1,2,4]triazolo[4,3-a]quinoxaline derivatives as DNA intercalators and Topoisomerase II inhibitors.
El-Adl K; El-Helby AA; Sakr H; Elwan A
Bioorg Chem; 2020 Dec; 105():104399. PubMed ID: 33113414
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of human DNA topoisomerase IIα by two novel ellipticine derivatives.
Vann KR; Ergün Y; Zencir S; Oncuoglu S; Osheroff N; Topcu Z
Bioorg Med Chem Lett; 2016 Apr; 26(7):1809-12. PubMed ID: 26906637
[TBL] [Abstract][Full Text] [Related]
11. Novel xanthone-polyamine conjugates as catalytic inhibitors of human topoisomerase IIα.
Minniti E; Byl JAW; Riccardi L; Sissi C; Rosini M; De Vivo M; Minarini A; Osheroff N
Bioorg Med Chem Lett; 2017 Oct; 27(20):4687-4693. PubMed ID: 28919339
[TBL] [Abstract][Full Text] [Related]
12. A structure-based 3D-QSAR study of anthrapyrazole analogues of the anticancer agents losoxantrone and piroxantrone.
Liang H; Wu X; Guziec LJ; Guziec FS; Larson KK; Lang J; Yalowich JC; Hasinoff BB
J Chem Inf Model; 2006; 46(4):1827-35. PubMed ID: 16859314
[TBL] [Abstract][Full Text] [Related]
13. Synthesis and cytotoxic activity of a new potential DNA bisintercalator: 1,4-Bis{3-[N-(4-chlorobenzo[g]phthalazin-1-yl)aminopropyl]}piperazine.
Galisteo J; Navarro P; Campayo L; Yunta MJ; Gómez-Contreras F; Villa-Pulgarin JA; Sierra BG; Mollinedo F; Gonzalez J; Garcia-España E
Bioorg Med Chem; 2010 Jul; 18(14):5301-9. PubMed ID: 20538470
[TBL] [Abstract][Full Text] [Related]
14. Design, synthesis, topoisomerase I & II inhibitory activity, antiproliferative activity, and structure-activity relationship study of pyrazoline derivatives: An ATP-competitive human topoisomerase IIα catalytic inhibitor.
Ahmad P; Woo H; Jun KY; Kadi AA; Abdel-Aziz HA; Kwon Y; Rahman AF
Bioorg Med Chem; 2016 Apr; 24(8):1898-908. PubMed ID: 26988802
[TBL] [Abstract][Full Text] [Related]
15. Synthesis and biological evaluation of N-(carbobenzyloxy)-l-phenylalanine and N-(carbobenzyloxy)-l-aspartic acid-β-benzyl ester derivatives as potent topoisomerase IIα inhibitors.
Han X; Zhong Y; Zhou G; Qi H; Li S; Ding Q; Liu Z; Song Y; Qiao X
Bioorg Med Chem; 2017 Jun; 25(12):3116-3126. PubMed ID: 28462840
[TBL] [Abstract][Full Text] [Related]
16. Chinese hamster ovary cells resistant to the topoisomerase II catalytic inhibitor ICRF-159: a Tyr49Phe mutation confers high-level resistance to bisdioxopiperazines.
Sehested M; Wessel I; Jensen LH; Holm B; Oliveri RS; Kenwrick S; Creighton AM; Nitiss JL; Jensen PB
Cancer Res; 1998 Apr; 58(7):1460-8. PubMed ID: 9537249
[TBL] [Abstract][Full Text] [Related]
17. Novel pyrazolo[3,4-d]pyrimidine with 4-(1H-benzimidazol-2-yl)-phenylamine as broad spectrum anticancer agents: Synthesis, cell based assay, topoisomerase inhibition, DNA intercalation and bovine serum albumin studies.
Singla P; Luxami V; Singh R; Tandon V; Paul K
Eur J Med Chem; 2017 Jan; 126():24-35. PubMed ID: 27744184
[TBL] [Abstract][Full Text] [Related]
18. Synthesis, Biological Evaluation and Molecular Docking Study of Cyclic Diarylheptanoids as Potential Anticancer Therapeutics.
Lu Y; Yin W; Alam MS; Kadi AA; Jahng Y; Kwon Y; Rahman AFMM
Anticancer Agents Med Chem; 2020; 20(4):464-475. PubMed ID: 31763968
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and biological evaluation of C1-O-substituted-3-(3-butylamino-2-hydroxy-propoxy)-xanthen-9-one as topoisomerase IIα catalytic inhibitors.
Park S; Hong E; Kwak SY; Jun KY; Lee ES; Kwon Y; Na Y
Eur J Med Chem; 2016 Nov; 123():211-225. PubMed ID: 27484510
[TBL] [Abstract][Full Text] [Related]
20. Mechanisms of Action and Reduced Cardiotoxicity of Pixantrone; a Topoisomerase II Targeting Agent with Cellular Selectivity for the Topoisomerase IIα Isoform.
Hasinoff BB; Wu X; Patel D; Kanagasabai R; Karmahapatra S; Yalowich JC
J Pharmacol Exp Ther; 2016 Feb; 356(2):397-409. PubMed ID: 26660439
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
